Inhalon
Lakshmi Botta has worked for several renowned companies in the biopharmaceutical industry. lakshmi started their career as a Lab Technician at Merck Millipore in 2008 and worked there until 2009. lakshmi then joined Adnexus Therapeutics as a Research Associate in 2011 and stayed until 2012. In 2013, Lakshmi joined Pfizer as a Senior Associate Scientist and held this position until 2017. lakshmi then worked as an Analytical Chemist II at Bristol-Myers Squibb from 2017 to 2018. Lakshmi further advanced their career at Catalent Pharma Solutions, where they worked as a Scientist from 2018 to 2020. From 2020 to 2021, they were a Senior Scientist at Istari Oncology. Currently, Lakshmi is employed as a Senior Scientist at Inhalon Biopharma starting from August 2021.
Lakshmi Botta completed their Master's degree in Microbiology, General from Acharya Nagarjuna University from the years 2000 to 2002. Following that, they pursued a Graduate Certificate in Biotechnology and Bioprocess from the University of Massachusetts Lowell, which they obtained in the year 2004.
Inhalon
Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.